AEROVATE THERAPEUTICS INC. - COMMON STOCK

2.5400

04-February-25 12:24:56

15 minutes delayed

Stocks

-0.0500

-1.93%

Today's range

2.5400 - 2.6800

ISIN

N/A

Source

NASDAQ

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

15 Aug 2022 07:50:00 By Nasdaq GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

02 Jun 2022 08:00:02 By Nasdaq GlobeNewswire
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

16 May 2022 17:15:00 By Nasdaq GlobeNewswire
Aerovate Therapeutics Announces First Quarter 2022 Financial Results

16 May 2022 08:00:02 By Nasdaq GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2021 Financial Results

30 Mar 2022 16:45:00 By Nasdaq GlobeNewswire
Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference

02 Mar 2022 08:00:01 By Nasdaq GlobeNewswire
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

15 Dec 2021 08:00:01 By Nasdaq GlobeNewswire
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

17 Sep 2021 08:00:00 By Nasdaq GlobeNewswire
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

16 Aug 2021 08:00:01 By Nasdaq GlobeNewswire
Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors

19 Jul 2021 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.